{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T13:56:01Z","timestamp":1782741361022,"version":"3.54.5"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Iceland Research Fund"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ejps.2017.02.032","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T11:02:22Z","timestamp":1487934142000},"page":"46-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"special_numbering":"C","title":["Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation"],"prefix":"10.1016","volume":"102","author":[{"given":"Nobuko","family":"Hada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Joseph","family":"Netzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5946-5887","authenticated-orcid":false,"given":"Fanny","family":"Belhassan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence Paul","family":"Wennogle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-9752","authenticated-orcid":false,"given":"Sveinbj\u00f6rn","family":"Gizurarson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2017.02.032_bb0005","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1021\/mp200465c","article-title":"Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood\u2013brain barrier: a case study examining sorafenib efflux clearance","volume":"9","author":"Agarwal","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0010","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.ejps.2010.05.003","article-title":"Strategy for effective brain drug delivery","volume":"40","author":"Alam","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.02.032_bb0015","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.ijpharm.2003.09.017","article-title":"A microdialysis model to examine nasal drug delivery and olfactory absorption in rats using lidocaine hydrochloride as a model drug","volume":"269","author":"Bagger","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0020","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1006\/viro.1993.1248","article-title":"The olfactory nerve and not the trigeminal nerve is the major site of CNS entry for mouse hepatitis virus, strain JHM","volume":"194","author":"Barnett","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.ejps.2017.02.032_bb0025","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1111\/j.1471-4159.2007.04808.x","article-title":"Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec\u00ae) across the mouse blood-brain barrier","volume":"102","author":"Bihorel","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejps.2017.02.032_bb0030","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1038\/nn0602-849","article-title":"Sniffing neuropeptides: a transnasal approach to the human brain","volume":"5","author":"Born","year":"2002","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejps.2017.02.032_bb0035","doi-asserted-by":"publisher","first-page":"2577","DOI":"10.1158\/0008-5472.CAN-04-2416","volume":"65","author":"Breedveld","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejps.2017.02.032_bb0040","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1006\/taap.2000.9073","article-title":"Direct olfactory transport of inhaled manganese (54MnCl2) to the rat brain: toxicokinetic investigations in a unilateral nasal occlusion model","volume":"169","author":"Brenneman","year":"2000","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.ejps.2017.02.032_bb0045","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-2044.1988.tb09011.x","article-title":"Cocaine absorption from the nasal mucosa","volume":"43","author":"Bromley","year":"1988","journal-title":"Anaesthesia"},{"key":"10.1016\/j.ejps.2017.02.032_bb0050","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3233\/JAD-1998-1102","article-title":"Delivery of nerve growth factor to the brain via the olfactory pathway","volume":"1","author":"Chen","year":"1998","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.ejps.2017.02.032_bb0055","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s00280-003-0741-6","article-title":"Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588","volume":"53","author":"le Coutre","year":"2004","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejps.2017.02.032_bb0060","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1124\/jpet.102.045260","article-title":"Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux","volume":"304","author":"Dai","year":"2003","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.02.032_bb0065","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.02.032_bb0070","doi-asserted-by":"publisher","first-page":"3591","DOI":"10.1091\/mbc.E07-01-0035","article-title":"Gleevec increases levels of the amyloid precursor protein intracellular domain and of the amyloid-beta degrading enzyme neprilysin","volume":"18","author":"Eisele","year":"2007","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejps.2017.02.032_bb0075","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/S0006-8993(03)02401-6","article-title":"Characterisation of the brain multidrug resistance protein (BMDP\/ABCG2\/BCRP) expressed at the blood-brain barrier","volume":"971","author":"Eisenbl\u00e4tter","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejps.2017.02.032_bb0080","doi-asserted-by":"publisher","first-page":"351","DOI":"10.2165\/00023210-200620050-00002","article-title":"Inhibition of gamma-secretase as a therapeutic intervention for Alzheimer's disease: prospects, limitations and strategies","volume":"20","author":"Evin","year":"2006","journal-title":"CNS Drugs"},{"key":"10.1016\/j.ejps.2017.02.032_bb0085","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/0378-5173(96)04579-6","article-title":"Selective delivery of insulin into the brain: intraolfactory absorption","volume":"140","author":"Gizurarson","year":"1996","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0090","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jconrel.2005.08.020","article-title":"Cultured skin loaded with tetracycline HCl and chloramphenicol as dermal delivery system: mathematical evaluation of the cultured skin containing antibiotics","volume":"108","author":"Hada","year":"2005","journal-title":"J. Control. Release"},{"issue":"Suppl. 3","key":"10.1016\/j.ejps.2017.02.032_bb0095","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neurosci."},{"key":"10.1016\/j.ejps.2017.02.032_bb0100","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1038\/sj.leu.2402679","article-title":"Effects of imatinib on bone marrow engraftment in syngeneic mice","volume":"16","author":"Hoepfl","year":"2002","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2017.02.032_bb0105","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0928-0987(00)00087-7","article-title":"Transport of drugs from the nasal cavity to the central nervous system","volume":"11","author":"Illum","year":"2000","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2017.02.032_bb0110","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1056\/NEJM196801112780205","article-title":"Pathogenesis for viral infections of the nervous system","volume":"278","author":"Johnson","year":"1968","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2017.02.032_bb0115","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ijpharm.2008.07.030","article-title":"Pharmacokinetics and brain uptake of diazepam after intravenous and intranasal administration in rats and rabbits","volume":"364","author":"Kaur","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0120","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1124\/jpet.109.162321","article-title":"Kinetic analysis of the cooperation of p-glycoprotein (P-gp\/Abcb1) and breast cancer resistant protein (Bcrp\/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone","volume":"333","author":"Kodaira","year":"2010","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejps.2017.02.032_bb0125","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ijpharm.2008.03.029","article-title":"Intranasal nanoemulsion based brain targeting drug delivery system of risperidone","volume":"358","author":"Kumar","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0130","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S0168-3659(01)00480-1","article-title":"Role of transporters in the tissue-selective distribution and elimination of drugs: transporters in the liver, small intestine, brain and kidney","volume":"78","author":"Kusuhara","year":"2002","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ejps.2017.02.032_bb0135","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1093\/toxsci\/kfm061","article-title":"Evaluating transport of manganese from olfactory mucosa to striatum by pharmacokinetic modeling","volume":"97","author":"Leavens","year":"2007","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.ejps.2017.02.032_bb0140","doi-asserted-by":"publisher","first-page":"415","DOI":"10.3109\/10611869808997870","article-title":"Nasal route for direct delivery of solutes to the central nervous system: fact or fiction?","volume":"5","author":"Mathison","year":"1998","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2017.02.032_bb0145","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1007\/s11523-010-0160-7","article-title":"Novel targeted agents for platelet-derived growth factor receptor and c-KIT in malignant gliomas","volume":"5","author":"Morris","year":"2010","journal-title":"Target. Oncol."},{"key":"10.1016\/j.ejps.2017.02.032_bb0150","doi-asserted-by":"publisher","first-page":"12444","DOI":"10.1073\/pnas.1534745100","article-title":"Gleevec inhibits beta-amyloid production but not notch cleavage","volume":"100","author":"Netzer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejps.2017.02.032_bb0155","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1172\/JCI109509","article-title":"Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery","volume":"64","author":"Neuwelt","year":"1979","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.ejps.2017.02.032_bb0160","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/S0140-6736(01)06535-7","article-title":"Safety and efficacy of imatinib (ST1571) in metastatic gastrointestinal stromal tumours: a phase I study","volume":"358","author":"van Oosterom","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2017.02.032_bb0165","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ejps.2017.02.032_bb0170","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3109\/10611869909085506","article-title":"Transnasal delivery of 5-fluorouracil to the brain in the rat","volume":"7","author":"Sakane","year":"1999","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejps.2017.02.032_bb0175","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1002\/ana.22365","article-title":"What the halted phase III \u03b3-secretase inhibitor trial may (or may not) be telling us","volume":"69","author":"Schor","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.ejps.2017.02.032_bb0180","doi-asserted-by":"publisher","first-page":"46107","DOI":"10.1074\/jbc.M307757200","article-title":"Adipsin, a biomarker of gastrointestinal toxicity mediated by a functional gamma-secretase inhibitor","volume":"278","author":"Searfoss","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2017.02.032_bb0185","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00228-009-0621-z","article-title":"Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders","volume":"65","author":"Singh","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.02.032_bb0190","first-page":"140","article-title":"Intranasal delivery: an approach to bypass the blood brain barrier","volume":"36","author":"Talegaonkar","year":"2004","journal-title":"Indian J. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0195","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neuroscience.2008.01.013","article-title":"Delivery of interferon-beta to the monkey nervous system following intranasal administration","volume":"152","author":"Thorne","year":"2008","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejps.2017.02.032_bb0200","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2174\/1567201053586047","article-title":"Intranasal drug delivery for brain targeting","volume":"2","author":"Vyas","year":"2005","journal-title":"Curr. Drug. Deliv."},{"key":"10.1016\/j.ejps.2017.02.032_bb0205","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0378-5173(03)00341-7","article-title":"Profiles of methotrexate in blood and CSF following intranasal and intravenous administration to rats","volume":"263","author":"Wang","year":"2003","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejps.2017.02.032_bb0210","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1365-2125.2006.02719.x","article-title":"Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein","volume":"62","author":"Widmer","year":"2006","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ejps.2017.02.032_bb0215","doi-asserted-by":"publisher","first-page":"12876","DOI":"10.1074\/jbc.M311652200","article-title":"Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation","volume":"279","author":"Wong","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejps.2017.02.032_bb0220","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ijpharm.2006.12.040","article-title":"Dermatopharmacokinetics of salicylate following topical injection in rats: effect of osmotic pressure and injection volume on salicylate disposition","volume":"337","author":"Yoshida","year":"2007","journal-title":"Int. J. Pharm."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098717301094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T22:26:33Z","timestamp":1536013593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098717301094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":44,"alternative-id":["S0928098717301094"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2017.02.032","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nose-to-brain transport of imatinib mesylate: A pharmacokinetic evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2017.02.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}